
2025 Breast Cancer Symposium
September 26, 2025
The Waterview at Port Jefferson Country Club
Port Jefferson, NY
Improving Breast Cancer Care Through Collaboration
Please join us for the Stony Brook Cancer Center’s Breast Cancer Symposium, an inspiring day dedicated to celebrating groundbreaking advances in breast cancer research and fostering collaboration across disciplines. Attended by clinical and research scientists along with oncology physicians, fellows, residents, postdocs, graduate students, and laboratory staff from across the Stony Brook Cancer Center. T
In the last three decades, our understanding of breast cancer has increased dramatically, leading to major improvements in treatment and better patient outcomes. However, as our knowledge of breast cancer increases, new challenges for detection, treatment, and prevention arise. For this year’s Breast Cancer Symposium, we will bring together the expertise and strength of our clinical and basic researchers at Stony Brook to discuss these important challenges in breast cancer, provide an update on the important clinical trials ongoing at the university, and showcase their latest research aimed at overcoming them. The symposium will combine traditional short talk presentations with a poster session for junior investigators and will feature a keynote speaker in the emerging and exciting area of breast cancer dormancy. By bringing together the unique strengths of our clinical and basic breast cancer expertise, we hope to promote cross-disciplinary collaborations and define new translational projects that can help move us closer to a cure.
Areas of interest to be discussed:
Breast Cancer Clinical Trials at Stony Brook
New Approaches to Cancer Imaging
New Therapeutic Targets for Breast Cancer
Breast Cancer Dormancy
Keynote Speaker
Robert Schneider, PhD
Dr. Robert Schneider, PhD, is the Albert Sabin Professor of Molecular Pathogenesis and a Professor of Microbiology, and Radiation Oncology at NYU School of Medicine. Dr. Schneider’s group performs basic, translational, and clinical research on the molecular basis of metastatic breast cancers, the intersection with the immune response, adult tissue regeneration, and the development of new therapeutics in these areas, primarily focused on the control of mRNA translation and stability. He is the author of more than 200 peer-reviewed publications in leading journals, has been continuously funded by the NIH for more than 35 years, and has received a number of awards in recognition of his achievements including the 2019 American Cancer Society Cancer Researcher award. He is also a co-founding scientist of seven biotechnology/small companies including ImClone Systems (New York), PTC Therapeutics. (New Jersey), and most recently Regerna Therapeutics.
CALL FOR ABSTRACTS AND POSTERS
Submit an abstract and poster celebrating research, new discoveries, and achievements in medicine and science.
We encourage undergraduate and graduate students, postdoctoral associates, research specialists, and research scientists/assistant professors to submit an abstract and poster. Original research, case reports, and case series are welcome.
Abstract submission deadline: September 8, 2025
Poster submission deadline: September 26, 2025